Real-time AI-scored market movers with ± impact ratings from -100 to +100. Latest: Eli Lilly Announces Results From SURPASS-PEDS, The First Phase 3 Trial To Evaluate The Safety And Efficacy Of Mounjaro; Mounjaro Met The Primary And All Key Secondary Endpoints At 30 Weeks And Showed Sustained Improvement In Glycemic Control And Continued BMI Reduction Through The Study's 52-Week Extension; The Safety And Tolerability Profile Of Mounjaro Was Generally Consistent With Previous Adult Studies (Impact: +85). TezNewz delivers instant financial news analysis through Discord with sector-specific insights and comprehensive market intelligence.
Financial News with AI Impact Scores
Get real-time financial news with AI-powered impact analysis delivered through Discord
Today's Market Overview
TezNewz delivers AI-scored financial news with impact ratings from -100 to +100. Latest stories cover Healthcare, Basic Materials, Technology sectors. Top impact story: "Eli Lilly Announces Results From SURPASS-PEDS, The First Phase 3 Trial To Evaluate The Safety And Efficacy Of Mounjaro; Mounjaro Met The Primary And All Key Secondary Endpoints At 30 Weeks And Showed Sustained Improvement In Glycemic Control And Continued BMI Reduction Through The Study's 52-Week Extension; The Safety And Tolerability Profile Of Mounjaro Was Generally Consistent With Previous Adult Studies" with +85 impact score.
Join our Discord community for real-time alerts and discussions.
Eli Lilly and Company (NYSE: LLY) announced positive results from the SURPASS-PEDS trial, the first Phase 3 study evaluating Mounjaro (tirzepatide) in children and adolescents with type 2 diabetes. At 30 weeks, Mounjaro met its primary endpoint by reducing A1C by an average of 2.2% from a baseline of 8.05%, with 86.1% of participants on the 10 mg dose achieving an A1C of ≤6.5%. Additionally, the trial showed a significant average BMI reduction of 11.2% at 30 weeks, with improvements sustained through a 52-week extension.
Blue Gold Limited (NASDAQ: BGL) has signed a definitive Purchase Agreement with FGR Bogoso Prestea Limited to acquire up to a 90% interest in the Mampon Gold & Copper Mining Lease in Ghana's Ashanti Gold Belt. The acquisition will occur in two tranches, with the first tranche involving a $15 million payment for a 50% stake in the Licensing Company, payable through the issuance of 750,000 ordinary shares. The second tranche, an option exercisable within 12 to 18 months, will involve additional payments based on independently verified resource upgrades.
Palantir Technologies has expanded its defense contract with the UK government, coinciding with a visit from former President Donald Trump. The company is also increasing its investments in the region as part of this strategic move. The details of the financial figures related to the deal were not disclosed, but the expansion is expected to enhance Palantir's presence in the defense sector.
Vale reported a loss of $38 million linked to a corruption case in Brazil's mining sector. The company is facing significant challenges due to ongoing legal issues that have impacted its financial performance. The stock ticker for Vale is VALE.
Steven Cohen has reported a 9.1% passive stake in Aptevo Therapeutics (APVO) as of September 16, according to an SEC filing. This investment indicates Cohen's interest in the company, although no further details on the financial implications or strategic intentions were provided.
Pluri (NASDAQ: PLUR) reported a Q4 loss of $(1.00) per share, missing the analyst estimate of $(0.73) by 36.99%. This represents an improvement from a loss of $(1.07) per share in the same quarter last year. The company's quarterly sales were $398,000, falling short of the $400,000 estimate by 0.50%, but showing a significant increase of 314.58% compared to $96,000 in the previous year.
Nucor Corp (NYSE: NUE) has lowered its third-quarter earnings outlook, expecting earnings per share to be between $2.05 and $2.15, significantly below the $2.61 estimate. The company anticipates declines in earnings across all operating segments due to lower volumes and margin compression. Following this announcement, Nucor's stock fell by 5.11% in after-hours trading, reaching $135.50. The company is set to release its third-quarter financial results on October 27.
ATIF Holdings Limited (NASDAQ: ZBAI) has entered into a non-binding letter of intent to acquire 100% equity of Mask Global Market Co. through the issuance of ZBAI Class A ordinary shares. The final consideration will be determined based on ongoing due diligence and Mask Global's audited financial statements, with a valuation report estimating Mask Global's worth between $450 million and $550 million. The parties expect to finalize a definitive agreement within 60 days, subject to various conditions including board approvals and due diligence outcomes.
Bullish (NYSE: BLSH) reported Q2 earnings of 93 cents per share, a significant improvement from a loss of $1.03 per share in the same period last year. Revenue increased to $58.63 million, up from $49.57 million year-over-year. The company also noted a trading volume of $179.6 billion, compared to $133 billion last year, and anticipates Q3 revenue between $69 million and $76 million. Following the earnings report, BLSH stock rose 1.75% to $55.30 in extended trading.
Novo Nordisk's oral semaglutide 25mg, marketed as Wegovy in pill form, achieved a 16.6% weight loss in individuals with obesity according to a newly published study. The treatment also showed improvements in everyday physical activities and cardiovascular risk factors, with a safety profile consistent with the injectable version of Wegovy. The FDA is expected to complete its review of the New Drug Application for this once-daily pill formulation by the end of the year.
